Novo Nordisk Pharma (Singapore) Pte Ltd (Singapore)

Novo Nordisk Pharma (Singapore) Pte Ltd is the Singapore subsidiary of Novo Nordisk A/S, a global healthcare company specializing in the research, development, manufacturing, and commercialization of innovative therapies for chronic diseases. The company's portfolio focuses on diabetes care, obesity management, rare bleeding disorders including haemophilia, growth disorders, and other serious chronic conditions. Its product range includes insulin therapies, GLP-1 receptor agonists, growth hormone treatments, and biologic therapies supported by extensive clinical research and development. In Singapore, the company is responsible for regulatory registration, marketing, distribution, medical affairs, and stakeholder engagement with healthcare professionals and public health institutions. It operates within the broader Asia-Pacific framework of Novo Nordisk's global operations. Key assets include a globally recognized pharmaceutical portfolio, scientific expertise, clinical research backing, and strong partnerships within the healthcare ecosystem. Strategic positioning emphasizes patient-centered innovation, sustainable access to treatment, collaboration with healthcare systems, and long-term commitment to improving outcomes for chronic disease patients.